1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 (PLC-β3) (PLC-β3)

Human Phospholipase C beta 3 (PLC-β3) is a critical signaling enzyme that belongs to the phosphoinositide-specific phospholipase C family [1]. It functions by catalyzing the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into two essential second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) [1, 2]. This process is typically initiated by the activation of G protein-coupled receptors (GPCRs), where PLC-β3 is stimulated by Gq/11 alpha subunits or G-beta-gamma complexes [1]. The production of IP3 leads to the release of calcium from the endoplasmic reticulum, while DAG activates protein kinase C, together orchestrating a wide array of cellular responses including cell growth and immune activation [2]. PLC-β3 is highly expressed in hematopoietic cells and the central nervous system, playing a significant role in modulating nociception and opioid sensitivity [3]. Research indicates that dysregulation or loss of PLC-β3 is associated with myeloproliferative neoplasms and inflammatory conditions, making it a potential target for therapeutic intervention in oncology and immunology [4]. While specific clinical drugs targeting PLC-β3 are limited, small molecule inhibitors like U73122 are frequently used in research to study its complex signaling network [1, 3]. Sources: [1] UniProt (P51432); [2] GeneCards (PLCB3); [3] PubMed (PMID: 11590441); [4] PubMed (PMID: 21148331).

Other names

Phospholipase C-beta-3PLCB3Phosphoinositide phospholipase C-beta-3PLC-beta-3

PLC-β3 catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into the second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) upon activation by G-protein subunits (Gq or G-beta-gamma) [1, 2].